Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

28,775 28,651 28,734 28,637

(1) Includes $- and $77 as additional research and development expense,

which represents an estimate of the net payable due to Novartis of

ANA975 research and development costs for the three months ended

September 30, 2008 and 2007, respectively. Includes ($47) and ($514)

as an offset in research and development expense, which represents an

estimate of the net reimbursement by Novartis of ANA975 research and

development costs for the nine months ended September 30, 2008 and

2007, respectively.

(2) Includes non-cash operating expenses of $738 and $1,392 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and

$0.05 effect on basic and diluted net (loss) income per common share

for the three months ended September 30, 2008 and 2007, respectively.

Research and development expense and general and administrative

expense includes $326 and $412 of non-cash operating expenses

determined in accordance with SFAS No. 123(R) for the three months

ended September 30, 2008. Includes non-cash operating expenses of

$2,065 and $3,502 determined in accordance with SFAS No. 123(R) or

approximately $0.07 and $0.12 effect on basic and diluted net loss per

common share for the nine months ended September 30, 2008 and 2007,

respectively. Research and development expense and general and

administrative expense includes $949 and $1,116 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the nine

months ended September 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)


'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rancho BioSciences , the scientific ... Array Suite with tranSMART . Scientists that ... send data in tranSMART to Array Suite for further ... tranSMART including the new 1.2 release. Array Suite ... for the analysis of high dimensional quantification data, including ...
(Date:7/31/2014)... “Rapid technological advances will spread ... increasing unemployment, depressing American consumer spending and further ... Catch 22—we need automated manufacturing if we are ... says economist and corporate relocation expert Dr. Ron ... Pro-Business States for 2014, co-published with the American ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN iReport ... News. , Bill Bro, KCA CEO, says, “We’re pleased ... international news organization. When we began using iReport last month, ... program highlights news of an enzyme that is lost in ... Kidney Cancer News also presents a report on outcomes from ...
(Date:7/30/2014)... Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2014 on Wednesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2014 ...
Breaking Biology Technology:Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... PLYMOUTH MEETING, Pa., March 17 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... for the fourth quarter and fiscal year ended,December 31, 2008. , ... -- Fourth quarter revenues increased to $36.6 million, ... fourth quarter of 2007., -- Non-GAAP operating income, ...
... Biotek, an innovative Canadian biotechnology company focusing primarily ... protein purification, today announced the signing of an ... "EXQ") to supply RNA purification kits based on ... Denmark-based company active in the life sciences, diagnostics ...
... of 25 February 2009, Arpida communicated that the Board of ... the company,s future. , In preparation ... to update shareholders as follows: At the shareholders, meeting, the,Board ... following options or a combination thereof: , , ...
Cached Biology Technology:BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 3BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 4BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 5BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 6BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 7BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 8BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 9BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 10BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 11BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 12Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 2Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 3Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 4Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting 2
(Date:7/31/2014)... University researchers have completed a 20-year study that ... prairie at different times of the year. It ... spring time frame has no measurable negative consequences ... multiple benefits. , The study was conducted by ... Biological Station fire chief, and Joseph Craine, research ...
(Date:7/31/2014)... percent of animal models against the highly infectious and ... intestinal disease that kills approximately 30,000 Americans annually. The ... and Immunity . , In the study, the ... purified toxins produced by C. difficile , as ... model that mimics the human disease, after only two ...
(Date:7/31/2014)... Alexandre Edmond Becquerel first discovered the photovoltaic effect in ... the power of sunlight for its own purposes. In ... issue of the FASEB Journal , ... the power of sunlight by focusing on a naturally ... throughout evolution. This conservationor persistence over time and across ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists shine bright new light on how living things capture energy from the sun 2
... mice of immune cells that promote the formation of new ... painful condition associated with infertility that affects up to 15 ... of new blood vessels, or angiogenesis, is known to encourage ... led by Ofer Fainaru, MD, PhD, a research associate in ...
... Resilience and Adaptation Program at the University of ... from the National Science Foundation to address questions ... RAP focuses on answering questions of how global ... as indigenous subsistence hunting. Economic, cultural and ecological ...
... Fla. Shiny amber jewelry and a mucky Florida ... ecosystem that could be anywhere from 15 million to ... of Florida and the Museum of Natural History in ... such as beetles and small crustaceans unwittingly swim into ...
Cached Biology News:Immune cells promote blood vessel formation in mouse endometriosis 2Alaska graduate program in sustainability receives $3.2 million award 2Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... Complete kit for all types of yeast ... Choice of two ... self-activating baits , ... , Complete set ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: